ReviewMolecular biology reports2026
Research progress on active components from natural medicines inhibiting tumor via epigenetic regulation.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Tumor is a major disease that seriously threatens human health, and its occurrence and progression involve complex interactions between the genome, epigenome, and environmental factors. Epigenetic modifications-such as DNA methylation, histone modifications, non-coding RNA regulation, and mRNA modifications-play key roles in tumor progression, metastasis, and drug resistance. Natural medicines offer multi-target and holistic regulatory effects, showing unique advantages in cancer therapy. Emerging evidence suggests that natural medicines and its active components can exert anti-tumor activities by modulating epigenetic mechanisms. This review summarizes natural medicines-mediated epigenetic regulation against tumors. It details how natural medicines influences DNA methylation by suppressing DNA methyltransferases (DNMTs) and altering tumor suppressor gene promoter methylation. The modulation of histone modifications through targeting histone deacetylases (HDACs), histone lysine methyltransferases (HKMTs), and histone lysine demethylases (HKDMs) is also discussed. Furthermore, the review covers natural medicines's regulation of non-coding RNAs (e.g., lncRNAs, miRNAs, circRNAs) and their downstream pathways, as well as its role in mRNA modifications, notably N6-methyladenosine (m6A). Overall, this work highlights the epigenetic potential of natural medicines in tumor therapy, enhancing the mechanistic understanding of its anti-tumor effects and supporting natural medicines modernization and precision oncology. However, challenges remain due to natural medicines complexity and tumor epigenetic heterogeneity, calling for deeper investigation and clinical validation.
Indexed as
Identifiers
42068388What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.